SecBot SecBot
SECBOTREPLAY Home › Report › ONCY

ONCY · Oncolytics Biotech entered a clinical supply agreement with Coherus…

Oncolytics Biotech, Inc. · PRESS-RELEASE filed Nov 13, 2026 at 12:10 ET

At the news

NEUTRALIMPACT 3/10

PRESS-RELEASE filed Nov 13, 2026 at 12:10 ET

Oncolytics Biotech entered a clinical supply agreement with Coherus Oncology to evaluate its oncolytic virus pelareorep in combination with Coherus' PD-1 inhibitor LOQTORZI (toripalimab) in a Phase 2 study for second-line squamous cell anal carcinoma (SCAC). The study is expected to start in Q1 2027 at a U.S. cancer center, targeting patients who have progressed on first-line chemo-immunotherapy. This is a non-dilutive supply deal with no upfront payment or milestone disclosed, providing pelareorep access to a marketed checkpoint inhibitor for a new indication with no approved second-line therapy.

  • Clinical supply agreement with Coherus Oncology for LOQTORZI (toripalimab-tpzi) in combination with pelareorep
  • Study targets second-line squamous cell anal carcinoma (SCAC) patients who progressed on first-line chemo-immunotherapy
  • No approved therapy exists for second-line SCAC
  • Study expected to begin Q1 2027 at a U.S. cancer center (to be named)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access